» Articles » PMID: 34114493

Anticipated Impact of Stem Cell and Other Cellular Medicine Clinical Trials for COVID-19

Overview
Journal Regen Med
Specialty Biotechnology
Date 2021 Jun 11
PMID 34114493
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

There is a critical need for safe and effective treatments for COVID-19. One possible type of treatment is cellular medicine such as stem cell therapy, but its potential is unclear. Here, our aim was to assess the potential impact of the many cellular medicine trials for COVID-19. We collected and analyzed data for defined criteria from trial registries. Our data suggest that relatively few of these COVID-19 trials will produce high-level evidence, but that on average they may be somewhat more rigorous than typical cell therapy trials unrelated to COVID-19. Most COVID-19 cellular medicine trials have relatively low potential for rapid, concrete impact. We discuss the findings in the context of the cellular medicine field overall.

Citing Articles

Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.

Couto P, Al-Arawe N, Filgueiras I, Fonseca D, Hinterseher I, Catar R Front Immunol. 2023; 14:1200180.

PMID: 37415976 PMC: 10321603. DOI: 10.3389/fimmu.2023.1200180.


Ethical issues and public communication in the development of cell-based treatments for COVID-19: Lessons from the pandemic.

Turner L, Munsie M, Levine A, Ikonomou L Stem Cell Reports. 2021; 16(11):2567-2576.

PMID: 34653406 PMC: 8516140. DOI: 10.1016/j.stemcr.2021.09.005.